Infections and complications from severe disability are the greatest contributors to mortality among multiple sclerosis (MS) patients, according to a population-based study in British Columbia, Canada, which also found that ... Read more
As a 61-year-old woman diagnosed in 2010 with primary progressive multiple sclerosis (PPMS), I was overjoyed when the U.S. Food and Drug Administration (FDA) approved the therapy Ocrevus (ocrelizumab) in ... Read more
Striking similarities between patients with multiple sclerosis and a type of schizophrenia suggest the disorders are related, according to a review of a number of studies. Dr. Boris M. Arneth ... Read more
British military personnel are at significantly higher risk of dying from multiple sclerosis than people in other occupations, a study reports.
University of Southampton researchers had done a previous study ... Read more
Ocrevus (ocrelizumab) is a newly FDA-approved therapy for multiple sclerosis. It can be used to treat two forms of the disease: relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). MORE: Ocrevus ... Read more
A detailed analysis of relapsing and primary progressive multiple sclerosis (MS) patients in the three Phase 3 trials of Ocrevus (ocrelizumab) showed that the treatment did not significantly increase their ... Read more